A Study of GC203 TIL in PDCA (RJ)

This study is testing a personalized cancer immunotherapy called GC203 TIL — immune cells (tumor-infiltrating lymphocytes) taken from a patient's own tumor, genetically modified, and then infused back — for people with pancreatic ductal adenocarcinoma (a common and aggressive type of pancreatic cancer) that has not responded to standard treatments. **You may be eligible if...** - You are between 18 and 70 years old - You have a confirmed diagnosis of pancreatic ductal adenocarcinoma - You have already undergone tumor removal surgery so the modified immune cells can be manufactured - Your cancer has failed standard treatment regimens - You have at least one measurable tumor remaining - Your blood cell counts and organ function meet minimum thresholds - Your expected survival is at least 3 months - You are in good physical condition (ECOG score 0–1) **You may NOT be eligible if...** - You have not had tumor resection surgery (required to produce the cell therapy) - You have serious infections or significant organ failure - You have active autoimmune disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.